The global urothelial cancer treatment market is estimated to grow at a CAGR of around 12% during the forecast period. Urothelial cancer is also called transitional cell cancer. Urothelial cancer is a type of bladder cancer, 90% of the bladder cancer cases are accounted for it and globally urothelial cancer is the 9th most common malignancy. According to the National Cancer Institute (NCI), in 2019, estimated new cases of Bladder cancer were 80,470 and 17,670 were death cases. According to the American Cancer Society (ACS) in 2020, there will be around 81,400 new cases for bladder cancer. Among them, 62,100 are men and 19,300 are women.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/urothelial-cancer-treatment-market
The global urothelial cancer treatment market is segmented based on the therapy type that includes chemotherapy, immunotherapy, and others. The chemotherapy segment held a significant share in the therapy segment in 2018. Usually, cancer cells divide and grow very fastly, chemotherapy destroys the cancer cells and stops it from growing. Chemotherapy is of two types, which are Intravesical chemotherapy and Systemic chemotherapy. Intravesical chemotherapy is also called local chemotherapy, it is usually given by the urologists. In this treatment, only those superficial tumor cells are destroyed which come in contact with chemotherapy solution. Tumor cells in the bladder wall or tumor cells that have spread to other parts can’t be treated by Intravesical or local chemotherapy.
Secondary Sources Include:
Financial reports of companies involved in the market
Whitepapers research-papers, and news blogs
Company websites and their product catalogue
The report is intended for a healthcare service provider, medical device companies, government organizations for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.
A Full Report of Global Urothelial Cancer Treatment Market is Available at: https://www.omrglobal.com/industry-reports/urothelial-cancer-treatment-market
Market Overview and Insights
Scope of the Report
Analyst Insight & Current Market trends
Key Findings
Recommendations
Conclusions
Company Profiles
Adaptimmune Therapeutics Plc
Alligator Bioscience AB
Amgen, Inc.
AndroScience Corp.
AstraZeneca PLC
Bristol-Myers Squibb Co.
Eisai Co. Ltd.
Eli Lilly and Co.
F. Hoffmann-La Roche AG
GlaxoSmithKline PLC
Johnson & Johnson Service, Inc.
Merck & Co, Inc.
Novartis AG
Pfizer, Inc.
Sanofi S.A.
Sun Pharmaceutical Industries, Ltd.
Teva Pharmaceutical Industries, Ltd.
Vault Pharma, Inc.
Market Segmentation
Global Urothelial Cancer Treatment Market by Therapy
Chemotherapy
Immunotherapy
Others( Targeted Therapy & Radiation Therapy)
Regional Analysis
North America
United States
Canada
Europe
UK
Germany
Italy
Spain
France
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Global Urothelial Cancer Treatment Market – Segment by Region
North America
United States
Canada
Europe
Germany
United Kingdom
France
Spain
Italy
Rest of Europe
Europe
North-American
Japan
India
Rest of North-American
Rest of the World
Latin America
Middle East and Africa
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/urothelial-cancer-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email:
[email protected]
Contact no: +91 780-304-0404